Synerlab acquires Alcala Farma in Spain

French drugmaker Synerlab says it has acquired Alcala Farma, a prominent Spanish contract development and manufacturing organization (CDMO). Financial terms of the transaction were not disclosed.

Alcala Farma specializes in the development of proprietary formulation, which represents nearly 40% of its total 25 million euros ($26.8 million) in sales and a key lever for future growth. Alcala Farma’s current portfolio of pharmaceutical drugs comes in multiple dosage forms includes sterile products, oral liquids, oral solids and topical products. Manufacturing is covered by two production sites in Spain, with one specializing in soft gelatin capsules and the other covering more than 250 formulations and 3,500 references.

For Synerlab, which has sales of nearly 110 euros and over 700 employees across five production sites in France, Alcala Farma represents a first step in the group’s European development. Alcala Farma will reinforce Synerlab’s position through: